Systemic treatment, especially chemotherapy, is an indispensable step for curing or increasing survival in patients with lung cancer. However, resistance to chemotherapy is frequently observed; this can result in recurrence and metastasis [1, 2] . Therefore, exploration of molecular mechanisms involved in chemoresistance and further development of drugs and strategies that inhibit chemoresistance are a high priority for lung cancer therapy [3, 4] .
Introduction
Systemic treatment, especially chemotherapy, is an indispensable step for curing or increasing survival in patients with lung cancer. However, resistance to chemotherapy is frequently observed; this can result in recurrence and metastasis [1, 2] . Therefore, exploration of molecular mechanisms involved in chemoresistance and further development of drugs and strategies that inhibit chemoresistance are a high priority for lung cancer therapy [3, 4] .
The transcription factor NF-B is known to be involved in the transcriptional regulation of various genes involved in cell proliferation, angiogenesis, metastasis and apoptosis [5, 6] . Anti-apoptotic signalling by NF-B mediates resistance to chemotherapeutic drugs [7, 8] in ovarian cancer [9] [10] [11] , pancreatic cancer [12] , breast cancer [13, 14] and prostate cancer [15] 
, implying that inhibition of NF-B might be an effective treatment strategy for many resistant cancers. However, this has been challenged by evidence in other cell types; in neuroblastoma cells, NF-B activation induced p53-mediated apoptotic signalling in response to the chemotherapy agent Dox [16]. It is presently unclear which signalling events ultimately determine whether NF-B activation results in a pro-or anti-apoptotic response. The role of NF-B might depend on the conditions of other oncogenes such as Myc, P53 and Bcl2.
Specifically, aberrant expression of NF-B has been related to lung cancer development and progression. Our recent work revealed that nuclear RelA and cytoplasmic pI-B␣ were significantly associated with a poor prognosis [1] . Furthermore, activation of NF-B by chemotherapy can blunt the efficacy of the chemotherapy itself to induce death in lung cancer cells [17, 18] . [19] [20] [21] . Additionally, the use of drug combinations with non-overlapping toxicity profiles could 
The finding that NF-B is a key player in lung cancer survival has prompted researchers to explore drugs with NF-B suppression activity in order to directly kill the cancer or render it more vulnerable to chemotherapeutic agents

Cell cultures
The human lung adenocarcinoma cell line A549, squamous cell line NCI-H446 and A549 taxol-resistant derivative A549-T24 were selected for resistance to taxol in a stepwise manner and maintained in a final concentration of 24 
Statistical analysis
Statistical analysis was carried out using one-way ANOVA Fig. 2A ). Fig. 2A, . Paclitaxel-induced Bcl-xl expression was also reduced by (Fig. 2A) , whereas the amount of total I-kB␣ was not increased by paclitaxel treatment (Fig. 2A) .
Results
Paclitaxel treatment induces NF-B activation and up-regulates its regulatory target Bcl-xl
We first compared NF-B DNA-binding activities among the human lung cancer cell lines A549, NCI-H446 and A549-T24, which had demonstrated resistance to taxol treatment, in order to detect possible effects of paclitaxel on NF-B activity. As shown in Fig. 1, the specificity of NF-B was first evaluated by performing EMSA gel supershift and competition assays (Fig. 1A). Basal NF-B activity in A549 and NCI-H446 cells was not detectable. After exposure to 100 nmol/l paclitaxel for 12, 24 and 48 hrs, NF-B activity in A549 and NCI-H446 cells increased notably in comparison with the basal level. Although the basal level of NF-B activity in A549-T24 cells was higher than in A549 and NCI-H446 cells, NF-B activity in A549-T24 cells also increased after 24 hrs of paclitaxel treatment, albeit to a lesser degree (Fig. 1B). As expected, paclitaxel treatment transiently increased the amount of phosphorylated I-B␣ in A549 and NCI-H446 cells as detected by Western blotting. This was linked to a change in NF-B DNA binding activity; however the total I-B␣ was maintained at a high level similar to that without treatment, suggesting that paclitaxel did not affect the degradation of I-B␣ in A549 or NCI-H446 cells. Consistent with the NF-B DNA binding activity, the anti-apoptotic gene Bcl-xl was also up-regulated in response to paclitaxel treatment. Similar effects were also observed in the A549-T24 cells.
IKK kinase complex mediates paclitaxel-induced NF-B activation
To determine the involvement of IKK in the response to paclitaxel, phospho-IKK-␣ /␤ was detected by immunoblotting with specific antibodies. Levels of phosphorylated (active) IKK increased 24 hrs after exposure to paclitaxel. Specifically, IKK-␤ and not IKK-␣ was phosphorylated in response to paclitaxel treatment, consistent with the changes in NF-B and I-kB (
Next, we tested whether inhibition of IKK using an IKK inhibitor (BAY 11-7082) was sufficient to block paclitaxel-induced NF-B activation. IKK activity (indicated as phospho-IKK-␣/␤) was induced in human NSCLC cell lines by paclitaxel treatment and inhibited by BAY 11-7082, whereas levels of IKK proteins (indicated as IKK-␤) remained at the same level. As shown in
paclitaxel-induced NF-B activity measured with EMSA was abrogated by
We further performed a TUNEL assay to examine whether apoptosis could account for the cell growth inhibition in this system. As seen in Fig. 2B (Fig. 3A) . Incubation with 5 mol/l parthenolide for 24 hrs completely inhibited paclitaxel-induced activation of IKK activity (Fig. 3B) (Fig. 3A) .
Parthenolide sensitizes to paclitaxel-induced apoptosis
We further examined the involvement of parthenolide in sensitization to paclitaxel-induced apoptosis. Parthenolide induced cell growth inhibition in a concentration-and time-dependent manner, but at a concentration of 5 mol/l for 12 hrs, parthenolide did not significantly inhibit growth (Fig. 4A) (Fig. 4Cc) . These results are consistent with the EMSA data shown in Fig. 4Cb, and (Fig 5A) , confirming that the siRNA worked. (Fig. 5D) .
As expected, inhibition of NF-kB significantly augmented the response of A549 cells to paclitaxel as assessed by MTT assay, whereas it abolished the inhibitory effects of parthenolide or BAY 11 7082 even when used at high concentrations (Fig. 5B). We next used the TUNEL assay to examine whether induction of apoptosis could account for the cell growth inhibition observed in p65-silenced A549 cells. These cells showed strong induction of DNA fragmentation, indicating apoptosis (Fig. 5C). These results suggest that specific inhibition of NF-B activity, which regulates expression of the anti-apoptotic gene Bcl-xl, resulted in the induction of apoptosis. In order to further verify that parthenolide could sensitize the effects of paclitaxel via NF-B regulation, cells genetically silenced for NF-B were treated with parthenolide
Fig. 2 BAY 11-7082-mediated inhibition of IKK resulted in reduced induction of NF-B by paclitaxel. A549 cells with or without pre-treatment of 5 mol/l BAY 11-7082 were treated with 100 nmol/l paclitaxel for 24 hrs. (A) NF-B DNA binding activities in the nuclear extract and p-IKK-␣/␤, IKK-␤, phospho-I-B␣, I-B␣, Bcl-xl in the cytosolic extract were compared. The experiment was repeated with identical outcomes for at least three times, and a representative result is shown. B. TUNEL analysis with flow cytometry was carried out to evaluate induction of apoptosis. Columns, average values of at least three independent experiments performed in triplicate; bars, ϮS.E.M. #, P Ͻ 0.01 versus paclitaxel ϩ BAY 11-7082. and paclitaxel, or with BAY 11 7082 and paclitaxel. As expected, blockade of p65 resulted in the enhancement of paclitaxel-mediated apoptosis comparable to the one obtained with parthenolide or BAY 7082 pre-treatments. But also these pre-treatments do not further enhance paclitaxel-induced apoptosis when p65 is already blocked by siRNA
Effect of IKK inhibition on NF-B transcript target genes
To determine whether NF-B downstream target genes are up-regulated by parthenolide, we evaluated the expression of some endogenous genes known to be regulated by NF-B. These included pro-apoptotic genes such as like Fas, DR4 and DR5 as well as anti-apoptotic genes such as c-IAP1, c-IAP2, XIAP and Bcl-xl. As indicated in Fig. 6, incubation with parthenolide somewhat increased Fas, DR4 and DR5 protein levels. In contrast to the previous finding that exposure to paclitaxel induced up-regulation of the anti-apoptotic molecule Bcl-xl, incubation of A549 cells with parthenolide resulted in a marked decrease of Bcl-xl, c-IAP1 and c-IAP2 expression but XIAP expression had no obvious change (Fig. 6). The inhibition of anti-apoptotic molecules in A549 cells by paclitaxel was also abolished by transfection with IKK-␣ or IKK-␤ siRNA, single or in combination (Fig. 6). These results indicate that parthenolide can antagonize paclitaxel to diminish NF-B-activated anti-apoptotic molecule expression in A549 cells.
Mitochondrial apoptosis signalling cascade and effects of parthenolide
It has been reported that mitochondria play a minor role in paclitaxel-induced cell death of lung cancer cells [32, 33] . However, mitochondrial cytochrome c release during NF-B inhibition was described previously [34] . Therefore, we next evaluated the possible contribution of cytochrome c release and caspase activation
Fig. 3 Regulation of NF-B activation by parthenolide occurs through IKK inhibition. (A) A549 cells were pre-treated with 5 mol/l parthenolide for various times (left) and for 24 hrs at various concentrations (right) courses, then incubated with 100 nmol/l paclitaxel for 24 hrs. Equal amounts of nuclear and cytosolic extracts were subjected to electrophoretic mobility shift assay (EMSA) for NF-B binding and Western blotting for Bcl-xl, respectively. (B) A549 cells were alternatively pre-treated with either 5 mol/l parthenolide or 5 mol/l BAY 11-7082 for 24 hrs and then incubated with paclitaxel for 24 hrs. EMSA for NF-B binding and Western blotting for p-IKK-␣/␤ and Bcl-xl were performed. (C) Nuclear translocation of p65 was determined by indirect immunofluorescence. Representative fields show the exclusive cytoplasmic location of NF-B in untreated control (a) and parthenolide-treated cells (b). Nuclear accumulation of p65 was observed in paclitaxel-treated cells (c) but not in paclitaxelϩBAY 11-7082 pre-treated (d) or paclitaxelϩparthenolide pre-treated cells (e). All the experiments shown in this figure were carried out two to four times, producing similar outcomes, and one representative result is shown.
to the chemosensitization effect of parthenolide in A549 cells. A549 cells treated with paclitaxel only displayed a punctate staining pattern for cytochrome c (Fig. 7A) 
Discussion
In [35, 36] . We also found that I-B phosphorylation, which is catalysed by IKK (including IKK-␣ and IKK-␤) [37, 38] , was induced by paclitaxel treatment in parallel with NF-B activation. Therefore, it is conceivable that a drug that inhibits NFkB could inhibit or circumvent resistance to chemotherapeutic agents such as paclitaxel.
We further investigated an adjuvant approach to increase the efficacy of paclitaxel through inhibition of NF-B. We demonstrated that parthenolide, a promising new multifunctional anti-cancer drug previously proven to inhibit NF-B activity [39, 40] , could contribute to the sensitization of A549 cells to paclitaxelinduced apoptosis. We observed that the cytotoxic effects of paclitaxel were potentiated by pre-treatment with 5 mol/l parthenolide. [48] , ectopically expressed I-B␣M [49] [50] [51] or used the proteasome inhibitor PS-341 [52, 53] or I-B inhibitor 55] [33, 59] , even though paclitaxel-induced NF-B activity mediates inhibition of caspases [60, 61] [62, 63] . NF-B activation can result in the transcription of some anti-apoptotic genes such as Bcl-xl [5, 60, 61, 64] [65] [66] [67] [68] . Parthenolide, which can activate the IKK pathway and subsequently inhibit NF-B and its downstream antiapoptotic proteins, was also tested in cell lines derived from solid tumours [65, 68, 69] . The present study therefore suggests that parthenolide might be useful in combination therapy with paclitaxel; such a combination might limit adverse side effects.
